89bio announces appointment of e. morrey atkinson, ph.d.

San francisco, feb. 24, 2022 (globe newswire) -- 89bio, inc. (nasdaq: etnb), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the appointment of e. morrey atkinson, ph.d., to its board of directors. dr. atkinson currently serves as senior vice president, head of commercial manufacturing and supply chain of vertex pharmaceuticals.
ETNB Ratings Summary
ETNB Quant Ranking